A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma.

We have examined the efficacy, toxicity and host immunological response of two different dose schedules of interleukin 2 (IL-2) given subcutaneously, daily for 3 months in patients with renal cell carcinoma (RCC) or metastatic melanoma (MM). We also examined the effect of adding the immune modulator...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Ahmed, F. Y., Leonard, G. A., A'Hern, R., Taylor, A. E., Lorentzos, A., Atkinson, H., Moore, J., Nicolson, M. C., Riches, P. G., Gore, M. E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group 1996
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC2077131/
https://ncbi.nlm.nih.gov/pubmed/8855983
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge